Replies to post #6884 on AIkido Pharma Inc (AIKI)

[Viewmont]

I think this is why it spiked earlier.

Diamond Equity Research Publishes Report Valuing HOTH Common Stock at $7.00 Per Share


News provided by
Hoth Therapeutics, Inc.
Mar 16, 2020, 08:40 ET
Share this article


NEW YORK, March 16, 2020 /PRNewswire/ -- Diamond Equity Research, an equity research firm with a focus on micro capitalization and small capitalization public companies has released a comprehensive update note of Hoth Therapeutics, Inc. (NASDAQ: HOTH). The report includes detailed information on Hoth Therapeutics' business model and recent developments. More detailed information can be found in Diamond Equity Research's September 2019 initiation report.
The full research report is available by registering here. Highlights from the report include:
Hoth Therapeutics, Inc. has intensively collaborated with university research labs to develop their drug candidates. Although currently still in early development stages, the company is targeting large markets. HOTH expects to face significant competition from other current treatments and the development pipelines of large pharmaceutical companies and emerging biotechnology companies. It competes in an industry characterized by (1) rapid technological change, (2) evolving industry standards, (3) emerging competition, and (4) new product introductions. Large competitors will likely be equipped to (1) provide broader product lines with greater sales and marketing forces, (2) make larger investments in research and development, and (3) consummate more acquisitions to strengthen their drug portfolio.
That said, we believe HOTH is well positioned in the industry, with its (1) novel and differentiated potential treatment targeted at preventing the formation of bacterial biofilm and addressing the potential impairment of skin barrier function, (2) patented BioLexa Platform, which combines two existing approved drugs, enabling reliance on existing safety data for those drugs, which could result in faster regulatory approval, (3) strong intellectual property portfolio, including exclusive licenses to patents and trademarks, and (4) additional potential therapies targeting dermatological issues and genetic disorders, including diabetic ulcers, skin aesthetics, psoriasis, and food allergies. However, given the early stage of the company the company is suited for sophisticated institutional investors or high-risk tolerant retail investors.